Study of Carrageenan's Effect on Insulin Resistance in Humans
NCT ID: NCT02629705
Last Updated: 2018-10-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
20 participants
INTERVENTIONAL
2015-10-31
2018-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Carnitine Infusion and Insulin Resistance
NCT02722902
Carnitine Supplementation in Type 2 Diabetic Patients
NCT03230812
Effects of Resistant Starch in a Beverage on Post-prandial Glycemic and Insulinemic Responses
NCT02161250
Study of a Carbohydrate Drink in Adults
NCT04313920
Designer Functional Foods on Parameters of Metabolic and Vascular in Prediabetes
NCT02400450
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
PREVENTION
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group A
1. Placebo intervention
2. Assessment block (3 days)
3. Washout-phase of 21-35 days
4. Carrageenan intervention
5. Assessment block (3 days)
Carrageenan
Carrageenan 250 mg bid supplemented to a standard food
Placebo
Placebo (Mannitol/Aerosil) bid supplemented to a standard food
Group B
1. Carrageenan intervention
2. Assessment block (3 days)
3. Washout-phase of 21-35 days
4. Placebo intervention
5. Assessment block (3 days)
Carrageenan
Carrageenan 250 mg bid supplemented to a standard food
Placebo
Placebo (Mannitol/Aerosil) bid supplemented to a standard food
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Carrageenan
Carrageenan 250 mg bid supplemented to a standard food
Placebo
Placebo (Mannitol/Aerosil) bid supplemented to a standard food
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* any ongoing medication
* known infections
* known liver disease
* known renal insufficiency
* alcohol consumption over 30 g/d
* shift work
18 Years
50 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital Tuebingen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Robert Wagner, M.D
Role: PRINCIPAL_INVESTIGATOR
University of Tübingen, Department of Internal Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital Tübingen, Department of Internal Medicine
Tübingen, , Germany
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Wagner R, Buettner J, Heni M, Fritsche L, Kullmann S, Wagmuller M, Peter A, Preissl H, Machann J, Jumpertz von Schwartzenberg R, Birkenfeld AL, Pape UF, van Hall G, Plomgaard P, Haring HU, Fritsche A, Thompson KN, Klein R, Stefan N. Carrageenan and insulin resistance in humans: a randomised double-blind cross-over trial. BMC Med. 2024 Nov 26;22(1):558. doi: 10.1186/s12916-024-03771-8.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CGN
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.